Astellas Pharma Inc. has posted positive topline data from its Phase III trial of antifungal agent isavuconazole against invasive aspergillosis study (SECURE). Isavuconazole is being co-developed with Basilea Pharmaceutica Ltd. The randomized, double-blind isavuconazole study (SECURE) achieved its primary objective in demonstrating non-inferiority versus voriconazole for the primary treatment of invasive fungal disease caused by Aspergillus species or certain other filamentous fungi. Isavuconaz...